Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
AssigneeNewsouth Innovation Pty Limited
InventorsLindsay Edward Wu, David A. Sinclair
Life of this patent
Estimating the term…
Abstract
Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive performance, in a subject in need thereof are disclosed. The disclosed methods include the step of administering to the subject an effective amount of an agent that increases the level of NAD+ in the subject.
Claims14
A method for prophylactically treating chemotherapy induced cognitive impairments (CICI) in a subject, comprising administering to a subject who has undergone exposure to a chemotherapy agent, is undergoing exposure to a chemotherapy agent, or will undergo exposure to a chemotherapy agent, an effective amount of an agent that increases the level of NAD+ in the subject, whereby chemotherapy agent-induced cognitive impairments (CICI) are prophylactically treated,
- wherein the agent that increases the level of NAD+ is an NAD+ precursor selected from nicotinamide mononucleotide (NMN), nicotinic acid, nicotinamide, nicotinamide riboside (NR), nicotinic acid mononucleotide, nicotinic acid riboside, 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), adenosine, adenine, and adenosine monophosphate.
Dependencies are inferred from the claim text.